E2F1 (Phospho-Thr433) ELISA Kit

General control non-derepressible 5 (GCN5) is ectopically expressed in different types of human cancer and association with the carcinogenesis, development, and poor prognosis of cancers. The present study was aimed to investigate the potential role and related mechanisms of GCN5 in IL-6-treated prostate cancer (PCa) cell. The results showed that an elevated GCN5 expression was stimulated by IL-6. Knockdown of GCN5 significantly inhibited IL-6-driven proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). Moreover, early growth response-1 (Egr-1) expression was elevated by IL-6 treatment and GCN5 siRNA down-regulated the expression of Egr-1. Furthermore, overexpression of Egr-1 attenuated the effects of GCN5 silence on cell proliferation, migration, invasion, and EMT in PCa. Besides, knockdown of GCN5 resulted in the down-regulation of p-Akt and up-regulation of PTEN, which was partly impeded by Egr-1 overexpression. The effects of GCN5 overexpression on cell proliferation and invasion were suppressed by LY294002, In conclusion, these data demonstrated the negative effect of up-regulated GCN5 in IL-6-induced metastasis and EMT in PCa cells through PI3K/PTEN/Akt signaling pathway down-regulating Egr-1 expression.

Maturity-onset diabetes of the young (MODY) is a monogenic subtype of diabetes mellitus. Although 14 genes were associated to different subtypes of MODY, 30-40% of MODY patients have unidentified genetic mutations. In this study, we conducted whole exome sequencing (WES) in four Turkish MODY suspected patients in two families who do not carry any pathological variants in four frequent MODY genes (HNF1A, GCK, HNF1B and HNF4A). Initially, the variants were scanned for the known 14 MODY genes and a gene set related to glucose metabolism. Secondly, the destructive (frameshift, inframe insertion/deletion, initiator codon variant, splice acceptor/ donor variant, stop gained/lost) and missense variants in novel candidate genes shared by two patients of the same family were assessed by different bioinformatic tools. As a result, a total of three rare and novel probably pathogenic heterozygous missense variants (p.His307Gln in c-Myc, p.Asp129Asn in CDK4 and p.Gly107Ser in ARHGDIA) in candidate genes were identified in two families. This study revealed the presence of nonsynonymous alterations in novel candidate genes which were implicated in the insulin secretion. This is the first WES study which reveals novel candidate genes in Turkish MODY patients although functional analyses are required to confirm the pathogenicity of these variants.